This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Retinitis pigmentosa (retinitis pigmentosa)Retinitis Pigmentosa (RP)

Contents and key points
ItemDetails
A. Classification codesICD-10: H35.51 | Special Copayment Reduction: V209 (5 years)
B. SynonymsRetinitis pigmentosa, RP, rod-cone dystrophy
C. Adult onsetLikely to first appear in adulthood — begins with night blindness in the teens to 30s; in some, onset in the 40s–50s; gradual progression over several decades
1. HistoryFirst named by Donders (1857); functional diagnosis after introduction of ERG (1940s); first RHO variant identified in 1989; in 2017, Luxturna (voretigene neparvovec) became the first gene therapy approved by the FDA
2. CausesPrimary degeneration of rods due to variants in more than 300 genes → subsequent secondary degeneration of cones; characteristic bone-spicule pigmentation; about 40% sporadic
3. GeneticsRPGR (X-linked), USH2A (autosomal recessive), RHO (autosomal dominant), PRPF31, EYS, CNGB1, PDE6A/B, etc.; X-linked·autosomal dominant·recessive·mitochondrial inheritance
4. EpidemiologyWorldwide prevalence about 1/4,000–5,000; estimated about 1.5 million people worldwide; the most common inherited retinal dystrophy; age of onset varies by mode of inheritance
5. PathophysiologyAbnormal rod phototransduction proteins → cell death (apoptosis) → reduced RPE function → secondary cone damage; involvement of oxidative stress, microglial activation, and the complement pathway
6. SymptomsNight blindness (early·most characteristic), tunnel vision (progressive loss of peripheral vision), photophobia, color vision abnormalities; late stage: reduced central vision; hearing loss accompanies in Usher syndrome
7. SignsFundus: peripheral bone-spicule pigmentation, optic disc pallor (waxy), retinal vascular attenuation; ERG: loss of rod responses
8. ScreeningERG·visual field testing for high-risk groups with a family history; hearing testing when Usher syndrome is suspected; early referral for night blindness symptoms in the teens
9. DiagnosisERG (full-field scotopic): loss/reduction of rod responses + fundus findings + visual field testing (Goldmann/automated) + gene panel (300+ genes)
10. TreatmentRPE65 variants: subretinal injection of voretigene neparvovec (Luxturna); general RP: vitamin A palmitate 15,000 IU/day; macular complications: anti-VEGF, carbonic anhydrase inhibitors; retinal prosthesis
11. PrognosisGradual progression over several decades; visual impairment in the 50s and reaching the legal blindness criterion in the 60s on average; sustained visual improvement in RPE65-RP patients with gene therapy (Luxturna)
12. PreventionUV protection (glasses blocking 99% of UV), no smoking, vitamin A maintenance, genetic counseling, preimplantation genetic diagnosis (PGD) available
13. References10 references listed with PMID/DOI (below)

1. Historical background

The name retinitis pigmentosa (RP) was first used in 1857 by the Dutch ophthalmologist Frans Cornelis Donders. However, the term 'retinitis', which implies an inflammatory disease, has been criticized as inappropriate since it became clear that the disease is actually a noninflammatory hereditary degeneration, and 'rod-cone dystrophy' has been proposed as a more accurate term, but the name RP continues to be used clinically. In the late 19th to early 20th century, the clinical association between ophthalmoscopic findings (bone-spicule pigmentation) and night blindness was established.

The introduction of the electroretinogram (ERG) in the 1940s enabled quantitative assessment of rod function, which became an objective tool for the diagnosis and follow-up of RP. A landmark turning point in genetic advances came in 1989, when the Pro23His variant of the RHO (rhodopsin) gene was identified as the first causative gene of autosomal dominant RP. Over the following 30 or so years, more than 300 causative genes were identified, including RPGR, USH2A, PRPF31, EYS, CNGB1, PDE6A, PDE6B, CNGA1, and ABCA4. In December 2017, the FDA's approval of voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) for retinal dystrophy associated with RPE65 gene variants as the first gene therapy for an inherited retinal disease became a milestone in the history of clinical treatment. In 2024–2025, next-generation therapies such as OCU400 (NR2E3-based gene-independent therapy), stem cell therapy, and CRISPR-based strategies are actively entering clinical trials.

2. Causes

RP is not a single-cause disease but a collective term for inherited retinal dystrophies caused by variants in more than 300 different genes. The common pathology is primary degeneration and loss of rod photoreceptors, followed by secondary damage to cone photoreceptors. Modes of inheritance vary, including autosomal recessive (about 50–60%), autosomal dominant (about 30–40%), X-linked (about 10–15%), and mitochondrial inheritance, and sporadic occurrence accounts for about 40%.

The causative genes are functionally involved in various pathways. These include phototransduction proteins (RHO, PDE6A, PDE6B, CNGA1, CNGB1, etc.), visual cycle proteins (RPE65, LRAT, RGR), ciliary structural proteins (RPGR, RP2, CEP290, TULP1, etc.), transcription factors (CRX, NRL), mRNA splicing factors (PRPF3, PRPF8, PRPF31, etc.), cell membrane proteins (ABCA4, BEST1), and extracellular matrix proteins (USH2A, VLGR1). Oxidative stress, mitochondrial dysfunction, and microglial activation act as secondary degeneration pathways.

3. Genetics

The genetics of RP are extremely heterogeneous, and more than about 300 gene loci have been identified to date (according to the RetNet database). The features of the major genes are as follows.

Genetic testing (next-generation sequencing, NGS panel or whole exome sequencing) can identify pathogenic variants in about 55–60% of patients, and the remaining 40–45% are not explained, owing to noncoding region variants, deep intronic variants, structural variants, etc.

4. General epidemiology

RP is the most common inherited retinal dystrophy, with a worldwide prevalence of about 1/4,000–1/5,000 (about 0.02–0.025%), and an estimated about 1.5 million people affected worldwide. Accurate prevalence data for Korea are limited, but based on rare disease center registrations, the number is estimated at several thousand.

Age of onset differs by mode of inheritance. X-linked RP (RPGR, etc.) commonly has a severe course with onset in the early teens, autosomal recessive RP (USH2A, EYS, etc.) mainly presents in the teens to 20s, and autosomal dominant RP (RHO, PRPF31, etc.) mainly in the 20s to 40s. Syndromic RP includes Usher syndrome (RP + hearing loss; about 20–25% of all RP), Bardet-Biedl syndrome (BBS; RP + obesity·polydactyly·intellectual disability·renal abnormalities), and Kearns-Sayre syndrome (mitochondrial; RP + external ophthalmoplegia·cardiac conduction abnormalities). Prevalence is similar in males and females, but males show a severe phenotype in the X-linked form.

5. Pathophysiology

The cell biological mechanisms of RP pathophysiology vary by causative gene, but the common final pathway is progressive apoptosis of rods followed by secondary damage to cones.

Primary rod degeneration

Defects in phototransduction pathway proteins: abnormal rhodopsin protein due to RHO variants causes accumulation in the endoplasmic reticulum (ER stress), promoting cell death via the UPR (unfolded protein response). With PDE6A/B variants, failure to terminate the phototransduction signal leads to persistently elevated cGMP → intracellular Ca²⁺ overload → apoptosis. Defects in ciliary structural proteins (RPGR, CEP290): blocked protein transport into the photoreceptor outer segment → abnormal outer segment formation → cell loss.

Impaired RPE-photoreceptor interaction

RPE65·LRAT defects block regeneration of 11-cis-retinal, making rhodopsin synthesis impossible. ABCA4 defects cause accumulation of toxic A2E lipofuscin in the RPE. RPE dysfunction impairs phagocytic processing of photoreceptor outer segments and nutrient supply, accelerating photoreceptor loss.

Secondary cone damage

After rod loss, cones lose trophic support due to interruption of the supply of RDCVF (rod-derived cone viability factor). Oxidative damage (increased retinal oxygen partial pressure), microglial activation and inflammatory cytokines (TNF-α, IL-1β), and complement pathway activation are secondary mechanisms promoting cone degeneration. This cone damage is the final stage leading to loss of central vision.

6. Symptoms

The symptoms of RP reflect the course of degeneration in the order rods → cones and progress gradually over several decades.

Early symptoms

Intermediate-stage symptoms

Late symptoms

Accompanying syndromic symptoms

7. Signs

Fundus findings (3 classic signs)

Findings of complications

Electrophysiological findings

On full-field ERG, loss or marked reduction of dark-adapted rod responses is the most sensitive functional indicator of RP. Light-adapted cone responses are relatively preserved early and lost with progression. Multifocal ERG (mfERG) assesses whether macular function is preserved.

8. Screening

Early screening for RP is important in clinically high-risk groups (positive family history, adolescents complaining of night blindness, patients with suspected Usher syndrome).

9. Diagnosis

The diagnosis of RP integrates clinical findings, electrophysiology, visual fields, and genetic testing.

Diagnostic criteria

Differential diagnosis

Supplementary tests

Fundus autofluorescence (FAF) assesses RPE status and the distribution of remaining photoreceptors. Whole exome sequencing or OCT to track whether the macula is preserved. Cascade testing of family members to detect asymptomatic carriers and early-onset cases.

10. Treatment

Gene-specific treatment

Nonspecific and adjunctive therapies

Assistive devices and rehabilitation

11. Prognosis

RP is a disease that progresses gradually over several decades, with large interindividual differences in the rate of progression. Generally, the average natural course begins with night blindness in the teens to 20s, followed by peripheral visual field constriction in the 30s to 40s, visual impairment in the 50s, and reaching the legal blindness criterion (visual field less than 10 degrees or corrected visual acuity 0.1 or less) in the 60s. However, differences by genotype are marked. The X-linked form (RPGR) is the most severe, sometimes reaching legal blindness in the 30s to 40s. Autosomal dominant RP (RHO Pro23His) progresses relatively slowly, with a longer period of preserved central vision.

Active management of complications (cystoid macular edema, cataract) can extend the period of preserved functional vision. In patients with RPE65 variants, sustained improvement in full-field light sensitivity has been reported at long-term (4–5 years) follow-up after Luxturna treatment, and the effect is particularly durable in children under 18. Vitamin A palmitate treatment has the effect of extending the period of preserved useful vision by several years on a scale of decades. For accurate individual prediction of visual prognosis, tracking quantitative biomarkers such as OCT ellipsoid zone width and visual field area, together with genetic confirmation, is important.

12. Prevention

Because RP is a disease of genetic cause, fundamental primary prevention is impossible. However, there are clinically important measures for slowing progression and preventing complications.

13. References

  1. Berson EL, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111(6):761-772. PMID: 8512476
  2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809. PMID: 17113430
  3. Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860. PMID: 28712537
  4. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132-141. PMID: 23701314
  5. Tanna P, et al. Retinitis pigmentosa: progression and treatment. Vision Res. 2017;137:27-36. PMID: 28438616
  6. Verbakel SK, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157-186. PMID: 29597005
  7. Fahim AT, et al. Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions. J Clin Med. 2025;14(16):5661. PMC: 12387042
  8. Scholl HP, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8(368):368rv6. PMID: 27928029
  9. Maguire AM, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2021;128(10):1433-1448. PMID: 33741217
  10. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40. PMID: 17032466